The analysis highlights the diversity of immune response in pancreatic cancer, and points toward the need for treatments tailored to individual patients.

Rather than attacking cancer cells directly, new cell-model research probes weaknesses in pancreatic cancer’s interactions with other cells to obtain nutrients needed for tumor growth.

The protein Argonaute 2 was found to be critical to the progression from benign lesions into pancreatic cancer, suggesting a therapeutic opportunity.

In mouse models, the work uncovers a new potential target to improve immunotherapy approaches to the deadly disease.

An early clinical trial at U-M finds that a Wee1 inhibitor, combined with radiation and gemcitabine, is safe and potentially effective in pancreatic cancer treatment.

Researchers have shown how tumor-associated macrophages release compounds that block gemcitabine in the most common type of pancreatic cancer